CytomX Therapeutics, Inc. (CTMX)
3.215
-0.20
(-5.99%)
USD |
NASDAQ |
Aug 28, 16:00
3.22
0.00 (0.00%)
After-Hours: 20:00
CytomX Therapeutics Free Cash Flow : -82.48M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -82.48M |
| March 31, 2026 | -80.19M |
| December 31, 2025 | -75.81M |
| September 30, 2025 | -72.35M |
| June 30, 2025 | -77.68M |
| March 31, 2025 | -81.54M |
| December 31, 2024 | -86.54M |
| September 30, 2024 | -88.78M |
| June 30, 2024 | -86.29M |
| March 31, 2024 | -92.34M |
| December 31, 2023 | -56.88M |
| September 30, 2023 | -36.22M |
| June 30, 2023 | -52.22M |
| March 31, 2023 | -61.18M |
| December 31, 2022 | -112.53M |
| September 30, 2022 | -142.39M |
| June 30, 2022 | -138.10M |
| March 31, 2022 | -131.77M |
| December 31, 2021 | -120.64M |
| September 30, 2021 | -107.08M |
| June 30, 2021 | -102.56M |
| March 31, 2021 | 22.81M |
| Date | Value |
|---|---|
| December 31, 2020 | 2.95M |
| September 30, 2020 | -9.36M |
| June 30, 2020 | -7.851M |
| March 31, 2020 | -153.90M |
| December 31, 2019 | -143.98M |
| September 30, 2019 | -143.66M |
| June 30, 2019 | -126.31M |
| March 31, 2019 | -104.81M |
| December 31, 2018 | -79.31M |
| September 30, 2018 | -27.68M |
| June 30, 2018 | -26.87M |
| March 31, 2018 | 173.48M |
| December 31, 2017 | 168.81M |
| September 30, 2017 | 148.38M |
| June 30, 2017 | 139.13M |
| March 31, 2017 | -18.37M |
| December 31, 2016 | -4.208M |
| September 30, 2016 | -13.89M |
| June 30, 2016 | -6.977M |
| March 31, 2016 | -29.25M |
| December 31, 2015 | -29.01M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Regeneron Pharmaceuticals, Inc. | 3.575B |
| ACADIA Pharmaceuticals, Inc. | 145.62M |
| Alnylam Pharmaceuticals, Inc. | 793.94M |
| Anika Therapeutics, Inc. | 0.562M |
| Savara, Inc. | -110.66M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -18.07M |
| Cash from Investing (Quarterly) | 5.953M |
| Cash from Financing (Quarterly) | 0.511M |
| Free Cash Flow Per Share (Quarterly) | -0.0825 |
| Free Cash Flow to Equity (Quarterly) | -20.92M |
| Free Cash Flow to Firm (Quarterly) | -18.07M |
| Free Cash Flow Yield | -14.03% |